Abstracts

Results In total, 527 patients were enrolled on the registry; of whom, 54 were excluded due to incomplete information. Out of 473 patients [Collagenous colitis 328(69%), Lymphocytic colitis 127(27%), 18 unspecified (4%)] included in the analysis, 358(76%) were female, aged 20–96 (median 67) years. Watery diarrhoea (463, 98%) and abdominal pain (111, 23%) were predominant symptoms. Weight loss was noted in 115 (24%).

Eight (2%) patients developed complications; 2 adverse drug reactions, 1 colorectal malignancy and 3 required surgical intervention for intractable symptoms related to MC.

Variations were noted in the following areas:

1. **Patient journey:** Whilst 230(49%) were referred directly to Gastroenterology, 109(23%) were referred initially to Surgery– with subsequent referral to Gastroenterology following colonoscopy. This led to delay in therapy initiation in a proportion of patients. In one unit, average length of symptoms at diagnosis was 5.7 months, with an average length of 9.1 months to see Gastroenterology.

2. **Medications:** There was no evidence of medication review in 121(26%) patients. Reducing-dose Budesonide was the first line treatment in 205(43%). Though 174(37%) did not require initial medical therapy; of these 18(10%) required subsequent treatment with Budesonide. There are 4(1%) patients on biologics and 4(1%) patients on immunomodulators specifically for MC– all of which were treated with budesonide first line.

3. **Follow-up:** A majority, 337(71%) were followed-up in clinic, with 260(77%) later discharged. Relapse was noted in 118 (25%) patients.

Conclusions Initial findings from the first MC Registry in the UK demonstrate variability in referral pathway, patient journey and management. Data suggests association with alarm features and significant complications.

REFERENCE

P109 
**VEDOLIZUMAB IS AN EFFECTIVE TREATMENT FOR ANTIBIOTIC REFRACTORY CHRONIC POUCHITIS**

1Sam Harrison*, 2Sara Cesano, 3Gareth-Rhys Jones, 4Philip Jenkinson, 2Alan Shand, 2Charlie Lees, 2Ian Arnott. 1University Of Edinburgh, Edinburgh, UK; 2Edinburgh IBD Unit – Western General Hospital, Edinburgh, UK

Abstract P109 Figure 1

Clinical sub-score. We also assessed blood tests including CRP, faecal calprotectin and inflammatory activity on pouch biopsy. In our statistical analysis continuous variables were assessed with paired samples t tests, whilst changes in frequencies were assessed with chi-squared tests. Adverse events were recorded quantitatively.

Results A total of 13 patients were included in the study. 6 females, median age 50 years (IQR 44.5–62). All patients underwent colectomy for failure of medical therapy. Following vedolizumab treatment, 92% of patients experienced a reduction in Pouchitis Activity Score clinical sub-score, with median score falling from 10 at baseline to 2.5 at follow up (p=0.0001, IQR= 8–12 at baseline, 0–5 at follow up). Median faecal calprotectin fell from 390μg/g to 197μg/g at 1 year (p=0.02, IQR= 340–644 at baseline, 60–283 at follow up). Active inflammation levels on pouch biopsy decreased in 71% of participants (Baseline- 4 mild, 1 moderate, 2 severe. Follow up- 3 mild, 4 none. Chi p= 0.0008. No serious adverse events were reported and only 15% of patients reported mild adverse events (1 arthropathy, 1 rhinitis).

Conclusions In our cohort, vedolizumab is an effective and safe treatment for chronic antibiotic refractory pouchitis and produces improvements in symptoms, biochemical tests and histological inflammation. Whilst larger studies are needed, this is a treatment option for those who have failed conventional medical therapy.

P110

**COST-EFFECTIVENESS OF A 17-GENE CLASSIFIER TO GUIDE TREATMENT CHOICE IN CROHN’S DISEASE IN THE UK**

1Susan Griffin, Vanessa Buchanan, 2James C Lee, 3Eoin F McKinney, 4Paul Kinnon, 1Karen Hills. 1Predictimmune, Cambridge, UK; 2Department of Medicine, University of Cambridge, Cambridge, UK; 3Cogenia Healthcare Consulting, Cambridge, UK

Introduction This study examines the cost-effectiveness of PredictSURE in guiding the early use of biologic therapy in newly diagnosed CD patients, at high-risk of requiring early and frequent treatment escalations in the UK. PredictSURE™ is a 17-gene, whole blood-based qPCR-based classifier that predicts long-term outcome in IBD, enabling early personalised treatment strategies through the early use of biologics in high-risk patients.

Methods A decision tree leading into a Markov state-transition model was constructed in MS Excel to compare two treatment approaches: 1) standard of care therapy following established